DNA methylation of nuclear receptor genes - Possible role in malignancy

Journal of Steroid Biochemistry and Molecular Biology

Volumn 80, Issue 1, 2002, Pages 1-11

  Berger, J ^a   Daxenbichler, G ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

DNA methylation; Malignancy; Nuclear receptors

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; DNA METHYLTRANSFERASE; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; RETINOIC ACID RECEPTOR; STEROID RECEPTOR; VITAMIN D RECEPTOR;

AGING; APOPTOSIS; BREAST CANCER; CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; DISEASE COURSE; DNA METHYLATION; DOWN REGULATION; GENE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; GROWTH REGULATION; HUMAN; NONHUMAN; PROTEIN FAMILY; REVIEW; TUMOR GROWTH;

AGING; CPG ISLANDS; DNA METHYLATION; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN;

EID: 0036182851     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00179-0     Document Type: Review

References (97)

1. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells
2. Number of CpG islands and genes in human and mouse
3. The DNA methylation machinery as a target for anticancer therapy
4. Tying it all together: Epigenetics, genetics, cell cycle, and cancer
5. DNA modification mechanisms and gene activity during development
6. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA
7. DNA methylation models histone acetylation
8. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
9. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
10. Histone acetylation: Influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression
11. DNA binding and methyl transfer catalysed by mouse DNA methyltransferase
12. Cloning, expression and chromosome locations of the human DNMT3 gene family
13. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foce
14. DNMT3a and DNMT3b are transcriptional repressors that exhibit unique localization properties to heterochromatin
15. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors
16. DNA methyltransferase expression and DNA methylation of CpG islands and peri-centromeric satellite regions in human colorectal and stomach cancers
17. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis
18. Abnormal patterns of DNA methylation in human neoplasia: Potential consequences for tumor progression
19. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas
20. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
21. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
22. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation
23. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells
24. Re-expression of endogenous p16INK4a in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state
25. Cancer epigenetics comes of age
26. Evidence for a direct growth-stimulating effect of estradiol on human MCF-7 cells in vivo
27. Steroid hormone receptors in breast cancer management
28. William L. McGuire memorial lecture. Anti-estrogens: Mechanisms of action and resistance in breast cancer
29. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer
30. Estrogen receptor gene methylation in human breast tumors
31. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
32. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression
33. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors
34. Mapping of ER gene CpG island methylation-specific polymerase chain reaction
35. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
36. DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers
37. Hypermethylation of the estrogen receptor alpha gene is not related to lack of receptor protein in human breast cancer
38. Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells
39. Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells
40. Growth factors in breast cancer
41. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression
42. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer
43. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue
44. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors
45. Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy
46. Relationship between DNA ploidy and functional estrogen receptors in operable prostate cancer
47. Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression
48. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma
49. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms
50. Concordant methylation of the ER and N33 genes in glioblastoma multiforme
51. Aging and DNA methylation in colorectal mucosa and cancer
52. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure
53. Assessment of hypermethylated DNA in two promoter regions of the estrogen receptor alpha gene in human endometrial diseases
54. Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5′ end of the ER gene
55. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
56. The inheritance of epigenetic defects
57. Life span prediction from the rate of age-related DNA demethylation in normal and cancer cell lines
58. Changes of the methylation pattern of the c-MYC gene during in vitro aging of IMR90 human embryonic fibroblasts
59. Age-dependent and tissue-specific changes of DNA methylation within and around the c-FOS gene in mice
60. Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro
61. The effect of tamoxifen and fenretinimide on human colorectal cancer cell lines in vitro
62. CpG island methylator phenotype in colorectal cancer
63. CpG island methylator phenotypes in aging and cancer
64. Stabilization of DNA methyltransferase levels and CpG island hypermethylation precede SV40-induced immortalization of human fibroblasts
65. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system
66. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia
67. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines
68. Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression
69. Distant metastases from prostatic carcinoma express androgen receptor protein
70. Androgen receptor defects: Historical, clinical, and molecular perspectives
71. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells
72. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells
73. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer
74. Inactivation of the human androgen receptor gene is associated with CpG hypermethylation in uterine endometrial cancer
75. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor
76. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells
77. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells
78. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer
79. Differential expression of nuclear retinoid receptors in normal, pre-malignant, and malignant head and neck tissues
80. A specific defect in the retinoic acid response associated with human lung cancer cell lines
81. Human lung cancer cell lines exhibit resistance to retinoic acid treatment
82. Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells
83. Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells
84. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine
85. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells
86. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer
87. Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer
88. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas
89. Hypermethylation of multiple genes in pancreatic adenocarcinoma
90. Organization of the human orphan nuclear receptor Nurr1 gene
91. The mouse Rxrb gene encoding RXR beta: Genomic organization and two mRNA isoforms generated by alternative splicing of transcripts initiated from CpG island promoters
92. At least three promoters direct expression of the mouse glucocorticoid receptor gene
93. The human mineralocorticoid receptor gene promoter: Its structure and expression
94. Characterization of a functional promoter for the human thyroid hormone receptor alpha (c-erbA-1) gene
95. Cloning and characterization of human estrogen receptor beta promoter
96. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers
97. Relationship between quantity of silver stained nucleolar organizer region associated proteins (Ag-NORs) and growth rate suppression of breast cancer cell lines after interferon-gamma and 4-hydroxy-tamoxifen treatment